Models:
Joseph Gordon
joseph-gordon/
ClinicalTrialsElig
0
Downloads: 1
[c09aa8]: / clusters / orderedclusters / clust_9.txt

Download this file

145 lines (144 with data), 9.7 kB 

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888

36.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this study

276.0

Breastfeeding should be discontinued if the mother is treated with indenoisoquinolines

74.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide

30.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888 and SCH727965

130.0

Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with vorinostat

40.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with veliparib; this may also apply to other agents used in this study

107.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this drug

132.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237

24.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib

55.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib

42.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775 (MK-1775)

36.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL184

72.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237 and/or romidepsin

42.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2171

73.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with belinostat

80.0

Patients who are nursing infants: breastfeeding should be discontinued if the mother is treated with the study agents

70.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenib

18.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ALT-803

12.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with the study drugs

68.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pomalidomide

63.0

Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the mother being treated with the study drugs

32.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent

40.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228) and ziv-aflibercept

57.0

Pregnant or nursing women; breastfeeding should be discontinued if the mother is treated with MLN0128

23.0

Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib

52.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib

90.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with terameprocol

23.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab

80.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib

135.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab

37.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with talazoparib (BMN 673)

66.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449

12.0

Breastfeeding should be discontinued if the mother is treated with sEphB4-HSA

42.0

Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228)

209.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TRC102

58.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR

30.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NT-I7

75.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128

30.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 and paclitaxel

33.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and necitumumab

82.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and navitoclax

50.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI-570

46.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with methoxyamine

15.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib and onalespib

46.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide

36.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks may also apply to other agents used in this study

90.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970)

45.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 (onalespib)

50.0

Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib

32.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970

46.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970) and/or gemcitabine

70.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab

29.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970

51.0

Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks also apply to the other agents used in this study, such as carboplatin and gemcitabine

150.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with any of these agents

48.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab

20.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with high dose nelfinavir

36.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated

38.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SGI-110

70.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib

24.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab

35.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinib

28.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab

40.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab and ipilimumab; these potential risks may also apply to blinatumomab

30.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab

60.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI4736 (durvalumab), tremelimumab and radiation

180.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab

48.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and/or bevacizumab

22.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BAL101553

30.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR

47.0

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PT2385

35.0